New combo therapy aims to fight aggressive lung cancer in japanese patients
NCT ID NCT06812260
First seen Nov 01, 2025 · Last updated May 08, 2026 · Updated 27 times
Summary
This study tests a new drug (HLX10) that helps the immune system fight cancer, combined with standard chemotherapy, in 26 Japanese patients with extensive-stage small cell lung cancer that hasn't been treated before. The main goal is to see how many patients' tumors shrink or disappear after 24 weeks. Researchers will also monitor side effects and how long patients live.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SCLC, EXTENSIVE STAGE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Kansai Medical University Hospital Department of Respiratory Oncology
RECRUITINGHirakata, Osaka, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.